These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12463418)

  • 1. The stability factor: importance in formulation development.
    Krishnamurthy R; Manning MC
    Curr Pharm Biotechnol; 2002 Dec; 3(4):361-71. PubMed ID: 12463418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical methods and formulation factors to enhance protein stability in solution.
    Jeong SH
    Arch Pharm Res; 2012 Nov; 35(11):1871-86. PubMed ID: 23212628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients.
    Jorgensen L; Hostrup S; Moeller EH; Grohganz H
    Expert Opin Drug Deliv; 2009 Nov; 6(11):1219-30. PubMed ID: 19678792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical degradation of proteins in the solid state with a focus on photochemical reactions.
    Mozziconacci O; Schöneich C
    Adv Drug Deliv Rev; 2015 Oct; 93():2-13. PubMed ID: 25481682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation.
    Cleland JL; Powell MF; Shire SJ
    Crit Rev Ther Drug Carrier Syst; 1993; 10(4):307-77. PubMed ID: 8124728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preformulation studies as an essential guide to formulation development and manufacture of protein pharmaceuticals.
    Volkin DB; Sanyal G; Burke CJ; Middaugh CR
    Pharm Biotechnol; 2002; 14():1-46. PubMed ID: 12189723
    [No Abstract]   [Full Text] [Related]  

  • 7. Solid-phase aggregation of proteins under pharmaceutically relevant conditions.
    Costantino HR; Langer R; Klibanov AM
    J Pharm Sci; 1994 Dec; 83(12):1662-9. PubMed ID: 7891292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arginine as an Excipient for Protein Freeze-Drying: A Mini Review.
    Stärtzel P
    J Pharm Sci; 2018 Apr; 107(4):960-967. PubMed ID: 29183741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of Protein Pharmaceuticals: Recent Advances.
    Manning MC; Holcomb RE; Payne RW; Stillahn JM; Connolly BD; Katayama DS; Liu H; Matsuura JE; Murphy BM; Henry CS; Crommelin DJA
    Pharm Res; 2024 Jul; 41(7):1301-1367. PubMed ID: 38937372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stabilization of therapeutic proteins by chemical and physical methods.
    Izutsu K
    Methods Mol Biol; 2005; 308():287-92. PubMed ID: 16082042
    [No Abstract]   [Full Text] [Related]  

  • 11. Advanced protein formulations.
    Wang W
    Protein Sci; 2015 Jul; 24(7):1031-9. PubMed ID: 25858529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation and manufacturability of biologics.
    Shire SJ
    Curr Opin Biotechnol; 2009 Dec; 20(6):708-14. PubMed ID: 19880308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Screening Tools Used in High-Concentration Protein Formulation Development.
    Hofmann M; Gieseler H
    J Pharm Sci; 2018 Mar; 107(3):772-777. PubMed ID: 29102552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Buffers in Protein Formulations.
    Zbacnik TJ; Holcomb RE; Katayama DS; Murphy BM; Payne RW; Coccaro RC; Evans GJ; Matsuura JE; Henry CS; Manning MC
    J Pharm Sci; 2017 Mar; 106(3):713-733. PubMed ID: 27894967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational Design of Liquid Formulations of Proteins.
    Manning MC; Liu J; Li T; Holcomb RE
    Adv Protein Chem Struct Biol; 2018; 112():1-59. PubMed ID: 29680234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of protein pharmaceuticals.
    Manning MC; Patel K; Borchardt RT
    Pharm Res; 1989 Nov; 6(11):903-18. PubMed ID: 2687836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forced degradation of therapeutic proteins.
    Hawe A; Wiggenhorn M; van de Weert M; Garbe JH; Mahler HC; Jiskoot W
    J Pharm Sci; 2012 Mar; 101(3):895-913. PubMed ID: 22083792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aseptic processing of protein pharmaceuticals.
    Townsend M
    Pharm Biotechnol; 2002; 14():129-89. PubMed ID: 12189724
    [No Abstract]   [Full Text] [Related]  

  • 19. Freeze drying of L-arginine/sucrose-based protein formulations, part I: influence of formulation and arginine counter ion on the critical formulation temperature, product performance and protein stability.
    Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
    J Pharm Sci; 2015 Jul; 104(7):2345-58. PubMed ID: 25994980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key interactions of surfactants in therapeutic protein formulations: A review.
    Khan TA; Mahler HC; Kishore RS
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):60-7. PubMed ID: 26435336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.